Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04310462 · ClinicalTrials.gov registry record · NA
Effectiveness of an EHR Interface to Reduce Dosage of Hydroxychloroquine
A NA study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- NA
- Development phase
- 65
- Enrollment target
NCT04310462 is a NA study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 65 participants.
The verdict
NCT04310462, a NA study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- NA
- Development phase
- 65 participants
- Enrollment target
Study Summary
Hydroxychloroquine (HCQ) is a disease-modifying, anti-rheumatic drug that regulates immune system activity and is typically prescribed to treat rheumatoid arthritis and systemic lupus erythematosus, as well as other immune conditions. Although generally well tolerated, study data have demonstrated that long-term use of HCQ may lead to irreversible and potentially vision-threatening retinal toxicity. The American Academy of Ophthalmology (AAO) issued guidelines in 2011, and again in 2016 that recommended dosing of HCQ be based on an individual's body weight, and also outlined how and when to screen for retinal toxicity. While clinicians have been aware of the potential side effects of HCQ for decades, studies have shown that many patients continue to receive higher than recommended doses. The goal of this study is to conduct a pragmatic trial to assess the utility of a new e-prescribing (eRX) interface for prescriptions of hydroxychloroquine (HCQ). The investigators will measure the effectiveness of the system in reducing the number of individuals prescribed HCQ over current guidelines by randomizing clinicians to the new interface. Ideally, the eRX interface will result in a lower number of potential adverse events (i.e. retinal toxicity) associated with high-dose, long-term use of HCQ.
Interventions
- OTHER New e-prescribing interface
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2024-02-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04310462
The ClinicalTrials.gov registry entry for NCT04310462 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which New e-prescribing interface is the first listed.
NCT04310462 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04310462 about?
NCT04310462 is a clinical study titled "Effectiveness of an EHR Interface to Reduce Dosage of Hydroxychloroquine". Hydroxychloroquine (HCQ) is a disease-modifying, anti-rheumatic drug that regulates immune system activity and is typically prescribed to treat rheumatoid arthritis and systemic lupus erythematosus, as well as other immune conditions. Although generally well tolerated, study data have demonstrated t...
What is the current status of trial NCT04310462?
This trial is currently terminated. It is a NA study. The enrollment target is 65 participants. The study started on 2017-02-01. Estimated completion is 2024-02-28.
What interventions are being tested in trial NCT04310462?
The interventions under investigation include: New e-prescribing interface (OTHER).
Who is sponsoring clinical trial NCT04310462?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.